



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE *SEP 29 2003*

In re Patent Application of:
Ruben et al.

Attny Docket No.: PZ029P2

Application No.: 10/050,873

Group Art Unit: 1647

Filed: January 18, 2002

Examiner: F. Hamud

For: Secreted Protein HOGCK20
(as amended)

INFORMATION DISCLOSURE STATEMENT (IDS)

Commissioner for Patents
Washington, D.C. 20231

Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. § 1.56 to inform the Patent and Trademark Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of a claim of the subject application, Attorneys for Applicants hereby direct the Examiner's attention to references AA-AO listed on the attached Form PTO/SB/08. A copy of each of references AA-AO is enclosed.

The above information is presented so that the Patent and Trademark Office can determine any materiality thereof to the claimed invention. See 37 CFR § 1.104(a) concerning the PTO duty to consider and use any such information. It is respectfully requested that the information be considered during the prosecution of this application.

Identification of the listed references is not to be construed as an admission of any individual associated with the filing or prosecution of the subject application that such references are available as "prior art" against the subject application. Furthermore, Applicants do not waive any rights to appropriate action to establish patentability over any of the listed documents should they be applied as references against the claims of the subject application.

Applicants respectfully request that the Examiner review the listed references and that the references be made of record in the file history of the application.

Pursuant to 37 C.F.R. § 1.97(b), since this information disclosure statement is being filed before the mailing date of a first Office Action on the merits, no fee is due in connection herewith. However, should the Patent Office determine otherwise, please charge the required fee to Human Genome Sciences, Inc., deposit account no. 08-3425.

Dated: September 16, 2003

Respectfully submitted,

By

Janet M. Martineau

Registration No.: 46,903
HUMAN GENOME SCIENCES, INC.
9410 Key West Avenue
Rockville, Maryland 20850
(301) 315-2723

KKH/JMM/KC/lcc

O I P E
S C I S
SEP 2 2 2003
P A T E N T & T R A D E M A R K S
Please type a plus sign (+) inside this box → +

PTO/SB/08 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

RECEIVED
SEP 29 2003
TECH CENTER 1600
1600 2900

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet	1	of	1	Attorney Docket Number	PZ029P2
-------	---	----	---	------------------------	---------

OTHER REFERENCES - NON PATENT LITERATURE DOCUMENTS					
Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
	AA	FOSSEY, S.C. <i>et al.</i> , "A High-Resolution 6.0-Megabase Transcript Map of the Type 2 Diabetes Susceptibility Region on Human Chromosome 20," <i>Genomics</i> . 76(1-3):45-57 (2001). (abstract)			
	AB	LAI, C-H. <i>et al.</i> , "Identification of Novel Human Genes Evolutionarily Conserved in <i>Caenorhabditis elegans</i> by Comparative Proteomics," <i>Genome Res.</i> 10(5):703-13 (2000).			
	AC	OHISHI, K. <i>et al.</i> , "PIG-S and PIG-T, Essential for GPI Anchor Attachment to Proteins, Form a Complex with GAA1 and GP18," <i>EMBO J.</i> 20(15):4088-98 (2001).			
	AD	OHISHI, K. <i>et al.</i> , "Two Subunits of Glycosylphosphatidylinositol Transamidase, GPI8 and PIG-T, Form a Functionally Important Intermolecular Disulfide Bridge," <i>J. Biol. Chem.</i> 278(16):13959-67 (2003).			
	AE	VAINAUSKAS, S. <i>et al.</i> , "Structural Requirements for the Recruitment of Gaa1 into a Functional Glycosylphosphatidylinositol Transamidase Complex," <i>J. Biol. Chem.</i> 277(34):30535-42 (2002).			
	AF	Genbank Accession No. NP_057021, "Phosphatidylinositol glycan class T precursor [Homo sapiens]," (September 2003).			
	AG	Genbank Accession No. NM_015937, "Homo sapiens phosphatidyl inositol glycan class T (PIGT), mRNA," (September 2003).			
	AH	Genbank Accession No. AX376166, "Sequence 233 from Patent WO0168848," (March 2002).			
	AI	Genbank Accession No. AF132940, "Homo sapiens CGI-06 protein mRNA, complete cds," (May 2000).			
	AJ	Geneseq Accession No. AAY66731, Genentech (1999).			
	AK	Geneseq Accession No. ABU59147, Genentech (2002).			
	AL	Geneseq Accession No. ABU59443, Genentech (2003).			
	AM	Geneseq Accession No. ABU60578, Genentech (2002).			
	AN	Geneseq Accession No. ABU92378, Genentech (2003).			
	AO	Geneseq Accession No. AAY76052, Genesis Res. & Dev. Corp. LTD (1999).			

Examiner Signature	Date Considered
--------------------	-----------------

¹ Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

² Unique citation designation number. ³ See attached Kinds of U.S. Patent Documents. ⁴ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁵ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁶ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.